Boehringer Ingelheim has joined forces with digital health firm Brainomix on a project to improve the care of people with fibrosing lung diseases in the US.
Artificial intelligence company Brainomix has claimed FDA approval for e-Lung, which assists in the diagnosis and assessment of patients with interstitial lung diseases (ILDs) from me
Artificial intelligence-powered software developed by Brainomix has been shown to identify patients with idiopathic pulmonary fibrosis (IPF) at risk of decline in a clinic
Two artificial intelligence-powered software tools – e-Stroke and RapidAI – have been recommended for use in the NHS to help detect stroke from CT brain scans by NICE.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
